Skip to main content
Celemics, Inc. logo

Celemics, Inc. — Investor Relations & Filings

Ticker · 331920 ISIN · KR7331920009 KO Manufacturing
Open in API
Filings indexed 181 across all filing types
Latest filing 2022-03-04 AGM Information
Country KR South Korea
Listing KO 331920

About Celemics, Inc.

https://www.celemics.com/

Celemics, Inc. is a biotechnology company that develops and provides Next-Generation Sequencing (NGS) solutions for research and clinical applications. The company specializes in hybridization-based target enrichment technology, offering a comprehensive portfolio of products and services. This includes ready-to-use and customized NGS panels, whole exome sequencing kits, library preparation kits, modular accessories, and bioinformatics analysis services. Celemics' solutions support a wide range of fields, including oncology (somatic cancer, liquid biopsy), inherited diseases, pathogen analysis, pharmacogenomics, and immune repertoire profiling. A key focus is the development of end-to-end customized target enrichment panels, providing support from assay design and optimization to complete bioinformatics analysis. The company's proprietary technologies in probe design and molecular barcoding enable efficient analysis of diverse and challenging sample types.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Celeomics. It details the date, location, and agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2022-03-04 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Celemix) announcing a significant change (over 30%) in revenue or profit structure. It provides preliminary financial figures (revenue, operating profit, net income) compared to the previous year, along with the reasons for the change. This is a standard 'Earnings Release' (ER) format used in the Korean market to disclose preliminary financial results before the final audited annual report is published. FY 2021
2022-02-04 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 1% confidence The document is a 'Single Sale/Supply Contract' announcement (단일판매ㆍ공급계약체결) filed by Celemix. It details a specific contract with the Korea Disease Control and Prevention Agency (KDCA) for genomic sequencing services. Since this is a regulatory disclosure of a specific business contract that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2022-01-03 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 1,000 characters) regarding the scheduling of an Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as date, location, purpose, and contact information, and explicitly states that the actual IR materials will be posted on the exchange website at a later time. Per the 'Menu vs Meal' rule, this is an announcement of an event/report rather than the presentation itself, and it fits the definition of a Regulatory Filing (RNS) as it is a formal notice of a corporate event.
2021-11-23 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Celemics' (주식회사 셀레믹스) covering the period from 2021.01.01 to 2021.09.30. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-15 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from the Korean DART system regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) and a subsequent amendment (정정신고) to that contract. It details the contract amount, counterparty (Korea Disease Control and Prevention Agency), and contract terms. Since this is a specific regulatory disclosure regarding a material business contract and does not fit into categories like financial reports, dividends, or management changes, it is classified as a general Regulatory Filing (RNS).
2021-11-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.